News

Medigene AG strengthens management with appointment of three Senior Vice Presidents

Martinsried/Munich, 11 January 2016. Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immunotherapy company focussing on the development of T cell-based immunotherapies for the treatment of cancer, announced today the expansion of the senior management team by appointing Dr. Dr. Olav Zilian as Senior Vice President Corporate Development, Dr. Kai Pinkernell as Senior Vice President/Chief Medical Officer (CMO) and Dr. Markus Dangl as Senior Vice President Research & Pre-Clinical Development. All of them have deep knowledge and many years of experience in the fields of immunotherapy and drug development.

Dr. Frank Mathias, CEO of Medigene AG, comments "The appointment of Dr. Zilian, Dr. Pinkernell and Dr. Dangl to the Medigene team is a next step in sharpening the company's focus on research, clinical development and commercialization of our innovative immunotherapies. The three managers bring further scientific and strategic expertise on board and will support the Management Board to drive forward the company's future success."

"We are very pleased that such high calibre international players in the pharma and life science sectors are joining Medigene, each bringing a unique set of skills to foster our next phase of clinical and commercial development," adds Prof. Dr. Dolores Schendel, CSO and designated CEO of Medigene AG. "We are thrilled to work with them and to jointly pursue our clinical development programs with the aim of establishing a long-term leading position in the field of immuno-oncology."

Dr. Olav Zilian joined Medigene effective 01 January 2016 and will drive forward the corporate development of the company. Dr. Zilian can look back on extensive experience in brokerage service, investment banking and consultancy from his past eleven years at the Swiss based Baader Bank subsidiary Helvea SA where he focused as Senior Analyst on sell-side research for European healthcare companies. Prior to this he worked as Research Assistant Professor at the Swiss Institute for Experimental Cancer Research (ISREC) where he headed and integrated a team of 12 collaborators at the interface of fundamental and applied research. Previously, he was a Postdoctoral Research Fellow in the Department of Molecular Oncology at Genentech Inc. in San Francisco, USA. Dr. Zilian studied medicine and holds a MD from the University of Basel, Switzerland and a PhD in molecular biology from the University of Zurich, Switzerland. He has received several awards for his analyst work, e.g. as "Europe No. 1 Stock Picker in Biotechnology" in 2014 and recently received an Executive Master of Business Administration from the International Institute for Management Development (IMD), Lausanne, Switzerland.

Dr. Kai Pinkernell will assume the position of Senior Vice President/Chief Medical Officer (CMO) at Medigene AG on 01 February 2016. With his long-term expertise in worldwide clinical development, clinical marketing and clinical sales as well as automation and GMP production of cellular therapies, he will be responsible for the clinical advancement of Medigene's immunotherapy platforms. Prior to joining Medigene, he held leading positions at Miltenyi Biotech GmbH, Bergisch Gladbach, Germany, most recently as Global Head of Clinical Business and Head of Clinical Development. Previously, Dr. Pinkernell has been with Cytori Therapeutics Inc., San Diego, USA, as Senior Director of Regenerative Cell Technology. He studied medicine and received his MD from the Westfaelische-Wilhems University in Muenster, Germany. Furthermore, Dr. Pinkernell holds a Master of Business Administration from the Marshall School of Business at the University of Southern California, Los Angeles, USA.
Dr. Markus Dangl will be taking up his new position as Senior Vice President Research & Pre-Clinical Development at Medigene AG on 1 March 2016. He brings deep knowledge in successfully leading multidisciplinary oncology research and translational medicine teams as well as managing external collaborations. Dr. Dangl held leading positions at Roche in the past 14 years, including the establishment of the Roche Translational Medicine Hub in Singapore where he was responsible for all research and translational medicine activities. Most recently he worked as Department Head DTA Oncology and Preclinical Science Leader MDM2 Franchise, Pharma Research and Early Development, Roche Diagnostics GmbH. He studied biochemistry and received a PhD in biochemistry from the Leopold-Franzens University of Innsbruck, Austria.

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development.  Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and EndoTAG® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01, Email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.